NEW ORLEANS, LA—Rivaroxaban is non-inferior to enoxaparin in short-term use and superior in long-term use for the prevention of venous thromboembolism (VTE) in acutely ill medical patients, but ...

Data from large Phase 3 studies showed that treatment with rivaroxaban was found to be safe and effective in older patients. Age does not appear to have a clinically significant impact on the safety ...

Please provide your email address to receive an email when new articles are posted on . “The approach of stopping a blood thinner and bridging with [enoxaparin] was used due to bleeding concerns with ...

Please provide your email address to receive an email when new articles are posted on . Overall, 1,144 bleeding events occurred by the 1-year follow-up period. There were 577 ischemic stroke or ...

XARELTO® (rivaroxaban) is safe to use in elderly patients with nonvalvular atrial fibrillation, an analysis published in Circulation finds. The ROCKET AF trial looked at patients over age 75, and ...

Studies offer insights for patients with atrial fibrillation and type 2 diabetes mellitus, with more results to come. A steady stream of follow-up research suggests that the novel oral anticoagulant ...

Rivaroxaban (Xarelto; Bayer/Janssen) is a reasonable alternative to warfarin for patients with atrial fibrillation/flutter and a bioprosthetic mitral valve, the randomized RIVER trial indicates.

The triple aim promised by healthcare reform-better quality care, greater patient satisfaction, at a lower cost-will play out procedure by procedure, as physicians find ways to deliver better care and ...

FDA Issues Complete Response Letters for Use of XARELTO® (rivaroxaban) to Reduce the Risk of Secondary Cardiovascular Events and Stent Thrombosis in Patients with Acute Coronary Syndrome RARITAN, N.J.

BOSTON, MA—For patients undergoing transradial coronary procedures, a short course of rivaroxaban (Xarelto; Bayer/Janssen) reduces the rate of radial artery occlusion without significantly increasing ...